New, oral treatment option for rheumatoid arthritis

Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well. However, if they do not respond and no remission or at least reduction in the activity of the disease can be achieved, they are given a combined treatment of methotrexate and a biologic agent if risk factors are present. An international research group has now shown that there is another, equally effective oral treatment option.

Leave a Reply

Your email address will not be published. Required fields are marked *